2[2]Eisen T,Bukowski RM,Staehler M,et al.Randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma (RCC):Impact of crossover on survival.ASCO,2006
4[4]Escudier B,Szczylik C,Eisen T,et al.Randomized phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 439006) in patients with advanced renal cell carcinoma(RCC).J Clin Oncol,ASCO Annual Meeting Proceedings,2005,23:16S[Supplement],LBA4510
5[5]Ratain MJ,Eisen T,Stadler WM,et al.Phase Ⅱ placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.J Clin Oncol,2006,24 (16):2505
6[6]Strumberg D,Richly H,Hilger RA,et al.Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006 in patients with advanced refractory solid tumors.J Clin Oncol,2005 10,23 (5):965
7[7]Biedrzycki BA.Renal cell carcinoma:Today's targeted therapies improving tomorrow's outcomes.ONS News.2006,21 (8Suppl):21 Available online at www.meniscus.com/eval/renal-cell-tx
8[8]Laura Wood,et al.Advances in the treatment of renal cell carcinoma.Optimizing outcomes.2006,the Meniscus Educational Institute Available Online at www.Meniscus.Com/eval/rcc-targeted-tx
9[9]Clark JW,Eder JP,Ryan D,et al.Safety and pharnacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor,BAY 43 -9006,in patients with advanced,refractory solid tumors.Clin Cancer Res,2005,11 (15):5472
1[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004 Oct 1; 64 (19):7099-109.
2[2]Strumberg D,Richly H,Hilger RA,et al.Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006in patients with advanced refractory solid tumors.J Clin Oncol,2005,23 (5):965
3[3]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC).J Clin Oncol,2005,23 (16S):Abstract 4544
4[4]Flaherty KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin (C) and paclitaxel (P)demonstrates preliminary antitumor activity in the expansion chort of patients with metastatic melanoma.Proc Am Society Clin Oncol,2004,23:Abstract 7507
5[5]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43 -9006) in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17 (5):866
6[6]Siu LL,Awada A,Takimoto CH,et al.Phase Ⅰ trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.Clin Cancer Res,2006,12 (1):144
7[7]Kupsch P,Henning BF,Passarge K,et al.Results of a phaseⅠ trial of sorafenib (BAY 43 -9006) in combination with oxaliplatin in patients with refractory solid tumors,including colorectal cancer.Clin Colorectal Cancer,2005,5 (3):188
8[8]Clark JW,Eder JP,Ryan D,et al.Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor,BAY 43 -9006,in patients with advanced,refractory solid tumors.Clin Cancer Res,2005,1; 11 (15):5472
9[9]Strumberg D,Awada A,Hirte H,et al.Pooled safety analysis of BAY 43 -9006 (sorafenib) monotherapy in patients with advanced solid tumors:Is rash associated with treatment outcome? Eur J Cancer,2006,42 (4):548
10[10]Eisen T,Bukowski RM,Staehler M,et al.Randomized phase Ⅲ trial of Sorafenib in advanced renal cell carcinoma(RCC):Impact of crossover on survival.Proc ASCO,2006,43:Abstr 4524
